Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PMCB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPharmaCyte Biotech dismisses CBIZ CPAs, hires Grassi & Co. as new auditor
Filed October 16, 2026 · Period ending October 14, 2026 · ~1 min read
Key Changes
-
high
Audit Committee dismissed CBIZ CPAs as independent auditor effective October 14, 2026.
Item 4.01 verify on EDGAR → -
high
Engaged Grassi & Co. as new auditor for fiscal year ending April 30, 2027 and interim reviews starting October 31, 2026.
Item 4.01 verify on EDGAR → -
medium
Dismissed auditor's reports for fiscal 2025 and 2026 were clean, with no adverse opinions or qualifications.
Item 4.01 verify on EDGAR → -
medium
Company notes it has identified material weaknesses in internal controls in the past and may do so again related to CFO segregation of duties and management review.
Item 4.01 verify on EDGAR → -
medium
No disagreements with CBIZ CPAs on accounting principles, disclosures, or audit scope.
Item 4.01 verify on EDGAR →
Summary
PharmaCyte Biotech dismissed its independent auditor, CBIZ CPAs, effective October 14, 2026, and engaged Grassi & Co. as its new auditor the same day. The change was initiated by the Audit Committee, not by the auditor.
The company stated that CBIZ's reports for fiscal years 2025 and 2026 were clean, with no adverse opinions or qualifications, and that there were no disagreements with CBIZ on accounting principles, financial statement disclosure, or auditing scope or procedure. These weaknesses were previously disclosed in the company's Annual Reports on Form 10-K for fiscal years 2025 and 2026.
The disclosure of material weaknesses is a concern for investors because it indicates that the company's financial reporting controls may not be effective, which could increase the risk of errors or fraud in financial statements. Investors should note that the auditor change itself appears to be a routine governance matter, but the ongoing material weaknesses in internal controls are a red flag that warrants attention. The company has not indicated any timeline for remediating these weaknesses, and the new auditor will need to assess the effectiveness of internal controls as part of its audit for fiscal year 2027.
Section-by-Section Diff
Event · Item 4.01 — Changes in Registrant's Certifying Accountant
PharmaCyte dismissed CBIZ CPAs and engaged Grassi & Co. as its new auditor, disclosing prior material weaknesses.
Added in current filing · verify on EDGAR →
there were (i) no “disagreements” (as defined in Item 304(a) (1) (iv) of Regulation S-K and the related instructions thereto) between the Company and CBIZ CPAs on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure
The company states there were no disagreements with CBIZ CPAs on accounting principles, financial statement disclosure, or auditing scope or procedure during the relevant periods. This is a standard disclosure required when changing auditors.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
neither the Company nor anyone acting on its behalf consulted with Grassi regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements
The company confirms it did not consult with Grassi on any accounting or auditing matters before engaging them. This is a standard disclosure indicating the new auditor was not involved in any prior decisions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Oct 16, 2026 · How we verify